Test Report Status

<u>Final</u>





**Biological Reference Interval** Units

PATIENT NAME : PRIYANKA KUMARI	<b>REF. DOCTOR :</b>	SELF
CODE/NAME & ADDRESS : C000138379	ACCESSION NO : 0065WL000686	AGE/SEX : 37 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : PRIYF10108665	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 09/12/2023 09:29:59
NEW DELHI 110030	ABHA NO :	REPORTED :11/12/2023 18:56:17
8800465156		
	<u> </u>	<u>l</u>

Results

F	IAEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECKUP B	ELOW 40FEMALE		
BLOOD COUNTS, EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD : CYANIDE FREE DETERMINATION	12.0	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD : FLUORESCENCE FLOW CYTOMETRY	4.14	3.8 - 4.8	mil/µL
WHITE BLOOD CELL (WBC) COUNT METHOD : ELECTRICAL IMPEDANCE	6.74	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD : ELECTRONIC IMPEDENCE & MICROSCOPY	107 Low	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD : CALCULATED PARAMETER	37.5	36 - 46	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	90.5	83.0 - 101.0	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED PARAMETER	28.9	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER	31.9	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	15.6 High	11.6 - 14.0	%
MENTZER INDEX	21.9		
MEAN PLATELET VOLUME (MPV) METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM	16.3 High	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS METHOD : FLUORESCENCE FLOW CYTOMETRY	61	40 - 80	%
LYMPHOCYTES METHOD : FLUORESCENCE FLOW CYTOMETRY	31	20 - 40	%
MONOCYTES METHOD : FLUORESCENCE FLOW CYTOMETRY	4	2 - 10	%
EOSINOPHILS METHOD : FLUORESCENCE FLOW CYTOMETRY	4	1 - 6	%

METHOD : FLUORESCENCE FLOW CYTOMETRY

Dr. Sushant Chikane **Consultant Pathologist** 





Details







#### **PATIENT NAME : PRIYANKA KUMARI REF. DOCTOR : SELF** CODE/NAME & ADDRESS : C000138379 ACCESSION NO : 0065WL000686 AGE/SEX :37 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : PRIYF10108665 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 09/12/2023 09:29:59 DELHI ABHA NO REPORTED :11/12/2023 18:56:17 : NEW DELHI 110030 8800465156 Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

	0		0/
BASOPHILS METHOD : FLUORESCENCE FLOW CYTOMETRY	0	0 - 1	%
ABSOLUTE NEUTROPHIL COUNT METHOD : CALCULATED PARAMETER	4.11	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT METHOD : CALCULATED PARAMETER	2.09	1.0 - 3.0	thou/µL
ABSOLUTE MONOCYTE COUNT METHOD : CALCULATED PARAMETER	0.27	0.2 - 1.0	thou/µL
ABSOLUTE EOSINOPHIL COUNT METHOD : CALCULATED PARAMETER	0.27	0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT METHOD : CALCULATED PARAMETER	0.00 Low	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR) METHOD : CALCULATED	1.9		
MORPHOLOGY			
RBC	Predominantly norm	ocytic normochromic.	
WBC	Normal morphology.		
PLATELETS	Mildly reduced in sm	ear. Macroplatelets are seen.	

**Interpretation(s)** BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait. WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.



Dr. Sushant Chikane **Consultant Pathologist** 



Page 2 Of 23





Vie<u>w Report</u>







PATIENT NAME : PRIYANKA KUMARI	REF. DOCTOR : S	SELF
	PATIENT ID : PRIYF10108665	AGE/SEX : 37 Years Female DRAWN :
DELHÍ		RECEIVED :09/12/2023 09:29:59 REPORTED :11/12/2023 18:56:17

Test Report Status	<u>Final</u>
--------------------	--------------

**Biological Reference Interval** Units

	HAEMATOLOGY		
MEDI WHEEL FULL BODY HEALTH CHECK	UP BELOW 40FEMALE		
ERYTHROCYTE SEDIMENTATION RATE (E	SR),EDTA		
E.S.R	29 High	0 - 20	mm at 1 hr
METHOD : AUTOMATED (PHOTOMETRICAL CAPILLARY STOP	PPED FLOW KINETIC ANALYSIS)		
GLYCOSYLATED HEMOGLOBIN(HBA1C), I BLOOD	EDTA WHOLE		
HBA1C	5.3	Non-diabetic Adult < 5.7 Pre-diabetes 5.7 - 6.4	%
		Diabetes diagnosis: > or =	6.5
		Therapeutic goals: < 7.0	
		Action suggested : > 8.0 (ADA Guideline 2021)	
METHOD : ION- EXCHANGE HPLC			
ESTIMATED AVERAGE GLUCOSE(EAG)	105.4	< 116	mg/dL

#### Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-**TEST DESCRIPTION** :-Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. **Decreased** in: Polycythermia vera, Sickle cell anemia

#### LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

**REFERENCE** :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

Diagnosing diabetes.
 Identifying patients at increased risk for diabetes (prediabetes).



Dr. Sushant Chikane **Consultant Pathologist** 



Page 3 Of 23

View Report







**REF. DOCTOR : SELF PATIENT NAME : PRIYANKA KUMARI** CODE/NAME & ADDRESS : C000138379 Female ACCESSION NO : 0065WL000686 AGE/SEX :37 Years ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : PRIYF10108665 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 09/12/2023 09:29:59 DELHI ABHA NO REPORTED :11/12/2023 18:56:17 : NEW DELHI 110030 8800465156 Test Report Status Results **Biological Reference Interval** <u>Final</u> Units

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for

eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c - 46.7

#### HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

Z.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
 Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates

addiction are reported to interfere with some assay methods, falsely increasing results. 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy



Dr. Sushant Chikane Consultant Pathologist



Page 4 Of 23

Vie<u>w Report</u>







**PATIENT NAME : PRIYANKA KUMARI REF. DOCTOR : SELF** CODE/NAME & ADDRESS : C000138379 ACCESSION NO : 0065WL000686 AGE/SEX :37 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : PRIYF10108665 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 09/12/2023 09:29:59 DELHI ABHA NO REPORTED :11/12/2023 18:56:17 : NEW DELHI 110030 8800465156

Test Report Status <u>Final</u> Results

**Biological Reference Interval** Units

### **IMMUNOHAEMATOLOGY** MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD 0 ABO GROUP METHOD : HAEMAGGLUTINATION (AUTOMATED) NEGATIVE RH TYPE

METHOD : HAEMAGGLUTINATION (AUTOMATED)

Interpretation(s) ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

**Dr. Sushant Chikane Consultant Pathologist** 



Page 5 Of 23

Report







PATIENT NAME: PRIYANKA KUMARI	<b>REF. DOCTOR :</b>	SELF
	ACCESSION NO : 0065WL000686	AGE/SEX : 37 Years Female
	PATIENT ID : PRIYF10108665	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 09/12/2023 09:29:59
NEW DELHI 110030	ABHA NO :	REPORTED :11/12/2023 18:56:17
8800465156		
	1	1

Test Re	eport	Status	<u>Final</u>
---------	-------	--------	--------------

**Biological Reference Interval** Units

	BIOCHEMISTRY			
MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE				
GLUCOSE FASTING, FLUORIDE PLASMA				
FBS (FASTING BLOOD SUGAR)	102 High	Normal <100 Impaired fasting glucose:10 125 Diabetes mellitus: > = 126 more than 1 occassion) (ADA guidelines 2021)		
METHOD : SPECTROPHOTOMETRY HEXOKINASE				
GLUCOSE, POST-PRANDIAL, PLASMA				
PPBS(POST PRANDIAL BLOOD SUGAR)	77	Normal <140 Impaired glucose tolerance:140 to 199 Diabetes mellitus : > = 200 (on more than 1 occassion) ADA guideline 2021		
METHOD : SPECTROPHOTOMETRY HEXOKINASE		5		
Comments				
NOTE : PLEASE CORRELATE GLUCOSE RESULTS WITH C LIPID PROFILE WITH CALCULATED LDL	LINICAL & THERAPEUTIC HISTO	DRY.		
CHOLESTEROL, TOTAL	165	Desirable : < 200 Borderline : 200 - 239 High : > / = 240	mg/dL	
METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC -	CHOLETSEROL OXIDASE, ESTERASE,	, PEROXIDASE		
TRIGLYCERIDES	185 High	Normal: < 150 Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500	mg/dL	
METHOD : SPECTROPHOTOMETRY, ENZYMATIC ENDPOINT WITH	GLYCEROL BLANK			
HDL CHOLESTEROL	40	At Risk: < 40 Desirable: > or = 60	mg/dL	
METHOD : SPECTROPHOTOMETRY, HOMOGENEOUS DIRECT ENZ	YMATIC COLORIMETRIC			

0.20 A

Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist

**PERFORMED AT :** Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062 Maharashtra, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Lab

Dr. Deepak Sanghavi

Chief Of Lab - Mumbai Refrence

Page 6 Of 23









PATIENT NAME : PRIYANKA KUMARI	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138379 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : <b>0065WL000686</b> PATIENT ID : PRIYF10108665 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :37 Years Female DRAWN : RECEIVED :09/12/2023 09:29:59 REPORTED :11/12/2023 18:56:17
Test Report Status Final	Results Biological	Reference Interval Units

CHOLESTEROL LDL	88	Optimal : < 100 Near optimal/above optimal 100-129 Borderline high : 130-159 High : 160-189 Very high : = 190	mg/dL :
METHOD : CALCULATED PARAMETER			
NON HDL CHOLESTEROL	125	Desirable : < 130 Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220	mg/dL
METHOD : CALCULATED PARAMETER			
VERY LOW DENSITY LIPOPROTEIN METHOD : CALCULATED PARAMETER	37.0 High	< or = 30.0	mg/dL
CHOL/HDL RATIO	4.1	Low Risk : 3.3 - 4.4 Average Risk : 4.5 - 7.0 Moderate Risk : 7.1 - 11.0 High Risk : > 11.0	
METHOD : CALCULATED PARAMETER		5	
LDL/HDL RATIO	2.2	Desirable/Low Risk : 0.5 - 3 Borderline/Moderate Risk : 3 - 6.0 High Risk : > 6.0	
METHOD : CALCULATED PARAMETER			

### Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Dr. Deepak Sanghavi

Chief Of Lab - Mumbai Refrence

Risk Category	
Extreme risk group	A.CAD with > 1 feature of high risk group
	B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or =
	50 mg/dl or polyvascular disease
Very High Risk	1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3.
	Familial Homozygous Hypercholesterolemia
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque
Moderate Risk	2 major ASCVD risk factors
Low Risk	0-1 major ASCVD risk factors

Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Lab

Page 7 Of 23











PATIENT NAME : PRIYANKA KUMARI	<b>REF. DOCTOR :</b> S	;ELF
CODE/NAME & ADDRESS : C000138379	ACCESSION NO : 0065WL000686	AGE/SEX : 37 Years Female
	PATIENT ID : PRIYF10108665	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 09/12/2023 09:29:59
NEW DELHI 110030	ABHA NO :	REPORTED :11/12/2023 18:56:17
8800465156		
· · · · · · · · · · · · · · · · · · ·	I	

Test	Report	Status	<u>Final</u>
------	--------	--------	--------------

Biological Reference Interval Units

Major ASCVD (Atherosclerotic o	ardiovascular disease)	Risk Fa	ictors		
1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use			tobacco use		
2. Family history of premature ASC	CVD		4. High bloor	d pressure	
5. Low HDL					
Newer treatment goals and statin in	itiation thresholds bas	sed on th	e risk categor	ies proposed by LA	I in 2020.
Risk Group	Treatment Goals			Consider Drug T	herapy
	LDL-C (mg/dl)	Non-H	DL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (0	Optional goal	>OR = 50	>OR = 80
	< OR = 30)	<or =<="" td=""><td>60)</td><td></td><td></td></or>	60)		
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or -<="" td=""><td>60</td><td>&gt; 30</td><td>&gt;60</td></or></td></or>	<or -<="" td=""><td>60</td><td>&gt; 30</td><td>&gt;60</td></or>	60	> 30	>60
Very High Risk	<50	<80		>OR= 50	>OR= 80
High Risk	<70	<100		>OR= 70	>OR=100
Moderate Risk	<100	<130		>OR=100	>OR=130
Low Risk	<100	<130		>OR=130*	>OR=160

\*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.35	Upto 1.2	mg/dL
METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -DIAZO METHOD			<i>.</i>
BILIRUBIN, DIRECT	0.13	< or = 0.3	mg/dL
METHOD : SPECTROPHOTOMETRY, JENDRASSIK & GROFF - DIAZOTI	ZATION		
BILIRUBIN, INDIRECT	0.22	0.0 - 0.9	mg/dL
METHOD : CALCULATED PARAMETER			
TOTAL PROTEIN	7.6	6.0 - 8.0	g/dL
METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -BIURET, REAGEN	IT BLANK, SERUM BLANK		
ALBUMIN	4.7	3.97 - 4.94	g/dL
METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - D	YE BINDING		
GLOBULIN	2.9	2.0 - 3.5	g/dL
METHOD : CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.6	1.0 - 2.1	RATIO
METHOD : CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	36 High	Upto 32	U/L
METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHAT	E ACTIVATION( P5P) - IFCC		
ALANINE AMINOTRANSFERASE (ALT/SGPT)	45 High	Upto 33	U/L
METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHAT	E ACTIVATION( P5P) - IFCC		
ALKALINE PHOSPHATASE	120 High	35 - 104	U/L
METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC	-		



Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist

g.s.

Dr. Deepak Sanghavi Chief Of Lab - Mumbai Refrence Lab



View Report

Page 8 Of 23

View Details View Repo





PATIENT NAME : PRIYANKA KUMARI		REF. DOCTOR : SELF	
CODE/NAME & ADDRESS : C000138379	ACCESSION NO : 00	55WL000686 AGE/S	SEX : 37 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : PRIYE		YF10108665 DRAW	/N :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECE	IVED :09/12/2023 09:29:59
NEW DELHI 110030	ABHA NO :	REPO	RTED :11/12/2023 18:56:17
8800465156			
Test Report Status <u>Final</u>	Results	Biological Refer	rence Interval Units
GAMMA GLUTAMYL TRANSFERASE (GGT)	27	< 40	U/L
METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC -	G-GLUTAMYL-CARBOXY-NITRO	NILIDE - IFCC	
LACTATE DEHYDROGENASE	196	< 223	U/L
METHOD : SPECTROPHOTOMETRY, LACTATE TO PYRUVATE - UV-I	FCC		
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN METHOD : SPECTROPHOTOMETRY, UREASE -COLORIMETRIC	9	6 - 20	mg/dL
CREATININE, SERUM			
CREATININE	0.77	0.60 - 1.10	mg/dL
METHOD : SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE K	INETIC - RATE BLANKED - IFCC-	IDMS STANDARIZED	
BUN/CREAT RATIO			
BUN/CREAT RATIO	11.69	8 - 15	
METHOD : CALCULATED PARAMETER			
URIC ACID, SERUM			
URIC ACID	3.8	2.4 - 5.7	mg/dL
METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC-	URICASE		
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.6	6.0 - 8.0	g/dL
METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -BIURET, REA	GENT BLANK, SERUM BLANK		
ALBUMIN, SERUM			
ALBUMIN	4.7	3.97 - 4.94	g/dL
METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG)	- DYE BINDING		
GLOBULIN			
GLOBULIN	2.9	2.0 - 3.5	g/dL
METHOD : CALCULATED PARAMETER			
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM METHOD : ISE INDIRECT	136	136 - 145	mmol/L
POTASSIUM, SERUM	4.20	3.5 - 5.1	mmol/L
METHOD : ISE INDIRECT			
CHLORIDE, SERUM	103	98 - 106	mmol/L
METHOD : ISE INDIRECT			
Interpretation(s)			
Sodium Potassium	c	hloride	



Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist

**PERFORMED AT :** Agilus Diagnostics Ltd Prime Square Building,Plot No 1,Gaiwadi Industrial Estate,S.V. Road,Goregaon (W) Mumbai, 400062 Maharashtra, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Lab

Dr. Deepak Sanghavi

Chief Of Lab - Mumbai Refrence

Page 9 Of 23

View Report









PATIENT NAME: PRIYANKA KUMARI	<b>REF. DOCTOR :</b> S	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ATIENT ID : PRIYF10108665	AGE/SEX : 37 Years Female DRAWN : RECEIVED : 09/12/2023 09:29:59 REPORTED :11/12/2023 18:56:17

Test	Report	Status	<u>Final</u>
------	--------	--------	--------------

**Biological Reference Interval** Units

Decreased In:CCF, cirrhosis,	Decreased in: Low potassium	Decreased In: Vomiting, diarrhea,
vomiting, diarrhea, excessive	intake,prolonged vomiting or diarrhea,	renal failure combined with salt
sweating, salt-losing	RTA types I and II,	deprivation, over-treatment with
nephropathy, adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chronic respiratory acidosis,
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
intoxication, SIADH. Drugs:	hyperglycemia), alkalosis, familial	sweating, SIADH, salt-losing
thiazides, diuretics, ACE inhibitors,	periodic paralysis, trauma	nephropathy, porphyria, expansion of
chlorpropamide, carbamazepine, anti	(transient).Drugs: Adrenergic agents,	extracellular fluid volume,
depressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
		hyperaldosteronism, metabolic
		alkalosis. Drugs: chronic
		laxative,corticosteroids, diuretics.
Increased in: Dehydration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
(excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA, dehydration,
vomiting or diarrhea), diabetes	acidosis, dehydration, renal failure,	overtreatment with
mellitus, diabetesinsipidus,	Addison's disease, RTA type IV,	saline, hyperparathyroidism, diabetes
hyperaldosteronism, inadequate	hyperkalemic familial periodic	insipidus, metabolic acidosis from
water intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
licorice,oral contraceptives.	potassium- sparing diuretics,NSAIDs,	alkalosis, hyperadrenocorticism.
	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide, and rogens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
hyperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
involves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
spurious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
falls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
mg/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignancy
	levels are normal.	(Normal serum chloride)

#### Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within

individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give vellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin is also elevated more than unconjugated (indirect) bilirubin is also elevated more than unconjugated (indirect) bilirubin excretion when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, is chemia to the liver, chronic



Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) **Consultant Pathologist** 

Dr. Deepak Sanghavi **Chief Of Lab - Mumbai Refrence** Lab





Vie<u>w Report</u>

Page 10 Of 23

Patient Ref. No. 775000005698676



DEE DOCTOD , SELE



DATTENT NAME - DDTVANKA KUMADT

		KEI DOCTOR : S			
CODE/NAME & ADDRESS : C000138379	ACCESSION NO :	0065WL000686	AGE/SEX	:37 Years	Female
	PATIENT ID :	PRIYF10108665	DRAWN	:	
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT II	D:	RECEIVED	:09/12/2023	09:29:59
NEW DELHI 110030	ABHA NO :		REPORTED	:11/12/2023	18:56:17
8800465156					
		1			
Test Report Status Final	Results	Biological	Reference	e Interval U	nits

hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver,kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels

(hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic

syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma,Waldenstroms disease

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

Dr. Apeksha Sharma D.P.B., DNB (PATH) (Reg.no.MMC2008/06/2561) **Consultant Pathologist** 

**PERFORMED AT :** Agilus Diagnostics Ltd Prime Square Building, Plot No 1, Gaiwadi Industrial Estate, S.V. Road, Goregaon (W) Mumbai, 400062 Maharashtra, India Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Lab

Dr. Deepak Sanghavi

Chief Of Lab - Mumbai Refrence

Page 11 Of 23



Vie<u>w Report</u>







PATIENT NAME : PRIYANKA KUMARI	REF. DOCTOR : S	SELF
	ACCESSION NO : 0065WL000686	AGE/SEX : 37 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : PRIYF10108665	DRAWN :
DELHÍ		RECEIVED :09/12/2023 09:29:59
NEW DELHI 110030	ABHA NO :	REPORTED :11/12/2023 18:56:17
8800465156		

Test Report Status Final

Results

Biological Reference Interval Units

CLINICAL PATH - URINALYSIS			
MEDI WHEEL FULL BODY HEALTH CHECKUP BEI	OW 40FEMALE		
PHYSICAL EXAMINATION, URINE			
COLOR	PALE YELLOW		
APPEARANCE	SLIGHTLY HAZY		
CHEMICAL EXAMINATION, URINE			
PH	5.5	5.00 - 7.50	
SPECIFIC GRAVITY	1.005 Low	1.010 - 1.030	
PROTEIN	NOT DETECTED	NOT DETECTED	
GLUCOSE	NOT DETECTED	NOT DETECTED	
KETONES	NOT DETECTED	NOT DETECTED	
BLOOD	NOT DETECTED	NOT DETECTED	
BILIRUBIN	NOT DETECTED	NOT DETECTED	
UROBILINOGEN	NOT DETECTED		
NITRITE	NOT DETECTED	NOT DETECTED	
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	
MICROSCOPIC EXAMINATION, URINE			
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	1-2	0-5	/HPF
EPITHELIAL CELLS	5-7	0-5	/HPF
CASTS	NOT DETECTED		
CRYSTALS	NOT DETECTED		
BACTERIA	NOT DETECTED	NOT DETECTED	
YEAST	NOT DETECTED	NOT DETECTED	
METHOD : URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEG	GRATED AUTOMATED SYSTEM		

#### Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment

Dr. Deepak Sanghavi Chief Of Lab - Mumbai Refrence Lab

Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist

Page 12 Of 23





View Details







PATIENT NAME : PRIYANKA KUMARI	REF. DOCTOR : S	SELF
	ACCESSION NO : 0065WL000686	AGE/SEX : 37 Years Female
	PATIENT ID : PRIYF10108665	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED :09/12/2023 09:29:59
NEW DELHI 110030	ABHA NO :	REPORTED :11/12/2023 18:56:17
8800465156		

Test Report	Status	<u>Final</u>
-------------	--------	--------------

**Biological Reference Interval** Units

Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Deepak Sanghavi Chief Of Lab - Mumbai Refrence Lab

Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist Page 13 Of 23





View Details







PATIENT NAME : PRIYANKA KUMARI	REF. DOCTOR : S	;ELF
CODE/NAME & ADDRESS : C000138379	ACCESSION NO : 0065WL000686	AGE/SEX : 37 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : PRIYF10108665	DRAWN :
DELHI		RECEIVED : 09/12/2023 09:29:59
NEW DELHI 110030	ABHA NO :	REPORTED :11/12/2023 18:56:17
8800465156		

Test Report Status **Final**  Results

**Biological Reference Interval** Units

,	
	CYTOLOGY
MEDI WHEEL FULL BODY HEALTH CHECKUP E	BELOW 40FEMALE
PAPANICOLAOU SMEAR	
TEST METHOD	CONVENTIONAL GYNEC CYTOLOGY
SPECIMEN TYPE	TWO UNSTAINED CERVICAL SMEARS RECEIVED (2CW- 32242)
REPORTING SYSTEM	2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY
SPECIMEN ADEQUACY	SMEARS ARE SATISFACTORY FOR EVALUATION.
MICROSCOPY	THE SMEARS SHOW MAINLY SUPERFICIAL SQUAMOUS CELLS, FEW INTERMEDIATE SQUAMOUS CELLS, OCCASIONAL SQUAMOUS METAPLASTIC CELLS, OCCASIONAL CLUSTERS OF ENDOCERVICAL CELLS IN THE MODERATE BACKGROUND OF POLYMORPHS.
INTERPRETATION / RESULT	NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY
-	REACTIVE CELLULAR CHANGES ASSOCIATED WITH INFLAMMATION (INCLUDES TYPICAL REPAIR - MODERATE INFLAMMATION)

#### Comments

Suggestions / Guidelines: (REF: THE BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY, 2014, 3rd Edition) ADVISED REPEAT SMEAR, AFTER TREATMENT OF INFLAMMATION.

1) Please note papanicolaou smear study is a screening procedure for cervical cancer with inherent false negative results, hence should be interpreted with caution.

2) No cytologic evidence of hpv infection in the smears studied.3) Primary screening of papanicolaou smears is carried out by cytotechnologist with 100% rescreening and reporting by surgical pathologist.



Dr. Roopali Manudhane **Consultant Histopathologist** 



Page 14 Of 23









PATIENT NAME : PRIYANKA KUMARI	<b>REF. DOCTOR :</b> S	; ELF
CODE/NAME & ADDRESS : C000138379	ACCESSION NO : 0065WL000686	AGE/SEX : 37 Years Female
F-703, LADO SARAI, MEHRAULISOUTH WEST		DRAWN :
DELHI		RECEIVED : 09/12/2023 09:29:59
NEW DELHI 110030	ABHA NO :	REPORTED :11/12/2023 18:56:17
8800465156		
	1	

**Test Report Status** <u>Final</u> Results

**Biological Reference Interval** Units

#### **CLINICAL PATH - STOOL ANALYSIS**

## MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

MICROSCOPIC EXAMINATION, STOOL

#### TEST CANCELLED AS SPECIMEN NOT RECEIVED

#### Interpretation(s)

REMARK

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION
Pus cells	Pus in the stool is an indication of infection
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days. Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.
Charcot-Leyden crystal	Parasitic diseases.
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.
Frank blood	Bleeding in the rectum or colon.
Occult blood	Occult blood indicates upper GI bleeding.
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.
рН	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.

### ADDITIONAL STOOL TESTS :

- Stool Culture:- This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if 1. treatment for GI infection worked.
- Fecal Calprotectin: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) 2. from Irritable Bowel Syndrome (IBS).

Dr. Ekta Patil,MD Microbiologist

Mumbai, 400062

Maharashtra, India





Page 15 Of 23







PATIENT NAME: PRIYANKA KUMARI	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138379 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : <b>0065WL000686</b> PATIENT ID : PRIYF10108665 CLIENT PATIENT ID:	AGE/SEX : 37 Years Female DRAWN : RECEIVED : 09/12/2023 09:29:59
NEW DELHI 110030 8800465156	ABHA NO :	REPORTED :11/12/2023 18:56:17
Test Report Status Final	Results Biological	Reference Interval Units

- Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia.
  Clostridium Difficile Toxin Assay: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to overuse of broad spectrum antibiotics which alter the normal GI flora.
- Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array Test, (Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus, parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
- <u>Rota Virus Immunoassay</u>: This test is recommended in severe gastroenteritis in infants & children associated with watery diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.



Dr. Ekta Patil,MD Microbiologist





View Report







PATIENT NAME: PRIYANKA KUMARI	REF. DOCTOR : SELF				
CODE/NAME & ADDRESS : C000138379	ACCESSION NO : 0065WL000686	AGE/SEX : 37 Years Female			
	PATIENT ID : PRIYF10108665	DRAWN :			
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 09/12/2023 09:29:59			
NEW DELHI 110030	ABHA NO :	REPORTED :11/12/2023 18:56:17			
8800465156					

Test Report	Status	<u>Final</u>
-------------	--------	--------------

Biological Reference Interval Units

#### **SPECIALISED CHEMISTRY - HORMONE** MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE THYROID PANEL, SERUM 68.6 Low ng/dL T3 Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester: 105.0 - 230.0 2nd Trimester: 129.0 - 262.0 3rd Trimester: 135.0 - 262.0 METHOD : COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNOASSAY T4 4.34 Low Non-Pregnant Women µg/dL 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70 METHOD : COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNOASSAY 20.100 High TSH (ULTRASENSITIVE) NonPregnant Women 0.27- µIU/mL 4.20 Pregnant Women (As per American Thyroid Association) 1st Trimester 0.100 - 2.500 2nd Trimester 0.200 - 3.000 3rd Trimester 0.300 - 3.000

METHOD : SANDWICH ELECTROCHEMILUMINESCENCE IMMUNOASSAY

#### Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

	[	Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
--	---	---------	-----	----------	-----	----------	---------------------

Dr%.

Dr. Deepak Sanghavi Chief Of Lab - Mumbai Refrence Lab

Harris

Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist





View Report

Page 17 Of 23

View Details





**REF. DOCTOR : SELF** 



# PATIENT NAME : PRIYANKA KUMARI

		-		
CODE/NAME & ADDRESS : C000138379	ACCESSION NO : 0065WL000686	AGE/SEX	:37 Years	Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030	PATIENT ID : PRIYF10108665	DRAWN	:	
	CLIENT PATIENT ID:	RECEIVED	:09/12/2023	09:29:59
	ABHA NO :	REPORTED	:11/12/2023	18:56:17
8800465156				

### Test Report Status Final

Results

**Biological Reference Interval** Units

1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
		1			hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
		1			thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
		1			inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

Dr. Deepak Sanghavi Chief Of Lab - Mumbai Refrence Lab



Dr. Apeksha Sharma D.P.B.,DNB (PATH) (Reg.no.MMC2008/06/2561) Consultant Pathologist Page 18 Of 23





View Report

View Details





PATIENT NAME : PRIYANKA KUMARI	REF. DOCTOR : SELF			
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: <b>0065WL000686</b> PATIENT ID : PRIYF10108665 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :37 Years Female DRAWN : RECEIVED :09/12/2023 09:29:59 REPORTED :11/12/2023 18:56:17		
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units		

MEDI WHEEL FULL BODY HEALTH CHECKUP BE XRAY-CHEST	LOW 40FEMALE				
IMPRESSION					
ECG	ESSION NO ABNORMALITY DETECTED				
ECG	WITHIN NORMAL LIMITS I	PLEASE CORRELATE CLINICALLY			
MEDICAL HISTORY					
RELEVANT PRESENT HISTORY	K/C/O THYROID SINCE 10 YEARS				
RELEVANT PRESENT HISTORY	NOT SIGNIFICANT				
RELEVANT PERSONAL HISTORY	NOT SIGNIFICANT				
MENSTRUAL HISTORY (FOR FEMALES)	REGULAR.				
RELEVANT FAMILY HISTORY	NOT SIGNIFICANT				
HISTORY OF MEDICATIONS	NOT SIGNIFICANT				
ANTHROPOMETRIC DATA & BMI					
HEIGHT IN METERS	1.55		mts		
WEIGHT IN KGS.	63		Kgs		
BMI	26	BMI & Weight Status as foll Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese	-		
GENERAL EXAMINATION					
MENTAL / EMOTIONAL STATE	NORMAL				
PHYSICAL ATTITUDE	NORMAL				
GENERAL APPEARANCE / NUTRITIONAL STATUS	OVERWEIGHT				
BUILT / SKELETAL FRAMEWORK	AVERAGE				
FACIAL APPEARANCE	NORMAL				
SKIN	NORMAL				
UPPER LIMB	NORMAL				
LOWER LIMB	NORMAL				
NECK	NORMAL				
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TEND	ER			
THYROID GLAND	NOT ENLARGED				
CAROTID PULSATION	NORMAL				

Page 19 Of 23



View Report View Details





PATIENT NAME : PRIYANKA KUMARI	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000138379	ACCESSION NO : 0065WL000686	AGE/SEX : 37 Years Female	
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : PRIYF10108665	DRAWN :	
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 09/12/2023 09:29:59	
NEW DELHI 110030	ABHA NO :	REPORTED :11/12/2023 18:56:17	
8800465156			
Test Report Status <u>Final</u>	Results Biolo	ogical Reference Interval Units	
TEMPERATURE	NORMAL		
PULSE	70/MIN, REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID BRUIT		
RESPIRATORY RATE	NORMAL		
CARDIOVASCULAR SYSTEM			
BP	110/70 MM HG (SUPINE)	mm/Hg	
PERICARDIUM	NORMAL		
APEX BEAT	NORMAL		
HEART SOUNDS	NORMAL		
MURMURS	ABSENT		
RESPIRATORY SYSTEM			
SIZE AND SHAPE OF CHEST	NORMAL		
MOVEMENTS OF CHEST	SYMMETRICAL		
BREATH SOUNDS INTENSITY	NORMAL		
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)		
ADDED SOUNDS	ABSENT		
PER ABDOMEN			
APPEARANCE	NORMAL		
VENOUS PROMINENCE	ABSENT		
LIVER	NOT PALPABLE		
SPLEEN	NOT PALPABLE		
HERNIA	ABSENT		
CENTRAL NERVOUS SYSTEM			
HIGHER FUNCTIONS	NORMAL		
CRANIAL NERVES	NORMAL		
CEREBELLAR FUNCTIONS	NORMAL		
SENSORY SYSTEM	NORMAL		
MOTOR SYSTEM	NORMAL		
REFLEXES	NORMAL		
MUSCULOSKELETAL SYSTEM			
SPINE	NORMAL		
JOINTS	NORMAL		

Page 20 Of 23



涩 View Report





Units

**Biological Reference Interval** 

#### **PATIENT NAME : PRIYANKA KUMARI REF. DOCTOR : SELF** CODE/NAME & ADDRESS : C000138379 ACCESSION NO : 0065WL000686 AGE/SEX :37 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : PRIYF10108665 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 09/12/2023 09:29:59 DELHI REPORTED :11/12/2023 18:56:17 ABHA NO : NEW DELHI 110030 8800465156

Results

# **BASIC EYE EXAMINATION**

<u>Final</u>

**Test Report Status** 

CONJUNCTIVA	NORMAL
EYELIDS	NORMAL
EYE MOVEMENTS	NORMAL
CORNEA	NORMAL
DISTANT VISION RIGHT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT (6/6)
DISTANT VISION LEFT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT (6/6)
NEAR VISION RIGHT EYE WITHOUT GLASSES	REDUCE VISUAL ACUITY (N/18)
NEAR VISION LEFT EYE WITHOUT GLASSES	REDUCE VISUAL ACUITY (N/18)
COLOUR VISION	OUT OF 17 NUMBERED PLATES 17
BASIC ENT EXAMINATION	
EXTERNAL EAR CANAL	NORMAL
TYMPANIC MEMBRANE	NORMAL
NOSE	NO ABNORMALITY DETECTED
SINUSES	NORMAL
THROAT	NO ABNORMALITY DETECTED
TONSILS	NOT ENLARGED
SUMMARY	
RELEVANT HISTORY	K/C/O THYROID SINCE 10 YEARS
RELEVANT GP EXAMINATION FINDINGS	REDUCE VISUAL ACUITY NEAR VISION BOTH EYES WITHOUT GLASSES ( N/18)
RELEVANT LAB INVESTIGATIONS	RAISED ESR(29). RAISED PLATELET COUNT(107). RAISED FASTING BLOOD SUGAR(102) RAISED EOSINOPHILS(5-7) RAISED SGPT(45) RAISED SGOT(36) RAISED ALKALINE PHOSPHATASE(120) RAISED TRIGLYCEDIDES(185) LOW T3(68.6) LOW T4(4.34) RAISED TSH(20.100)
RELEVANT NON PATHOLOGY DIAGNOSTICS	NO ABNORMALITIES DETECTED

Page 21 Of 23



Details





PATIENT NAME : PRIYANKA KUMARI	REF. DOCTOR : SELF			
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703. LADO SARAI, MEHRAULISOUTH WEST	ACCESSION NO: <b>0065WL000686</b> PATIENT ID : PRIYF10108665 CLIENT PATIENT ID: ABHA NO :	AGE/SEX : 37 Years Female DRAWN : RECEIVED : 09/12/2023 09:29:59 REPORTED :11/12/2023 18:56:17		
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units		

**REMARKS / RECOMMENDATIONS** 

REGULAR PHYSICAL EXERCISES / LOW CALORIC DIET REDUCE FATTY AND PROCESSED FOOD IN DIET REDUCE SUGARS, SWEETS IN DIET VISUAL ACUITY FOR CORRECTION FOLLOW UP WITH PHYSICIAN FOR RAISED TSH, LOW T3, T4 AND LOW PLATELET COUNT.

Page 22 Of 23





View Report

View Details



PERFORMED AT : Agilus Diagnostics Ltd. Plot No. 88, Road No. 15,Midc Estate,Andheri (East) Mumbai, 400093 Maharashtra, India Tel : 09152729959/9111591115, Fax : CIN - U74899PB1995PLC045956



#### **REF. DOCTOR : SELF PATIENT NAME : PRIYANKA KUMARI** CODE/NAME & ADDRESS : C000138379 ACCESSION NO : 0065WL000686 AGE/SEX :37 Years Female ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : PRIYF10108665 DRAWN : F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: RECEIVED : 09/12/2023 09:29:59 DELHI REPORTED :11/12/2023 18:56:17 ABHA NO **NEW DELHI 110030** : 8800465156

Results

Units

### MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

**Final** 

**ULTRASOUND ABDOMEN** 

#### ULTRASOUND ABDOMEN

NO ABNORMALITIES DETECTED TMT OR ECHO

#### **CLINICAL PROFILE**

Test Report Status

2D ECHO DONE NORMAL

#### Interpretation(s) MEDICAL

#### \*\*End Of Report\*\*

Please visit www.agilusdiagnostics.com for related Test Information for this accession

#### **CONDITIONS OF LABORATORY TESTING & REPORTING** 1. It is presumed that the test sample belongs to the patient 5. AGILUS Diagnostics confirms that all tests have been named or identified in the test requisition form. performed or assayed with highest quality standards, clinical 2. All tests are performed and reported as per the safety & technical integrity. turnaround time stated in the AGILUS Directory of Services. 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment interpreted by registered medical practitioners only to breakdown / natural calamities / technical downtime or any determine final diagnosis. 7. Test results may vary based on time of collection, other unforeseen event. 4. A requested test might not be performed if: physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor i. Specimen received is insufficient or inappropriate ii. Specimen quality is unsatisfactory or call us for any clarification. Test results cannot be used for Medico legal purposes. iii. Incorrect specimen type 8. iv. Discrepancy between identification on specimen 9. In case of queries please call customer care container label and test requisition form (91115 91115) within 48 hours of the report. **Agilus Diagnostics Ltd**

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Page 23 Of 23





View Report

View Details



PERFORMED AT : Agilus Diagnostics Ltd. Plot No. 88, Road No. 15,Midc Estate,Andheri (East) Mumbai, 400093 Maharashtra, India Tel : 09152729959/9111591115, Fax : CIN - U74899PB1995PLC045956